Adithya Gopinath, Adolfo Ramirez-Zamora, Stephen Franks, Tabish Riaz, Aidan Smith, Glen Dizon, Lauryn Hornstein, Jordan Follett, Camille Swartz, Jonathan Bravo, E Lee Kugelmann, Matthew Farrer, Michael S Okun, Habibeh Khoshbouei
BACKGROUND: Parkinson's disease (PD) is the second most common neurodegenerative disorder, with genetic factors accounting for about 15% of cases. There is a significant challenge in tracking disease progression and treatment response, crucial for developing new therapies. Traditional methods like imaging, clinical monitoring, and biomarker analysis have not conclusively tracked disease progression or treatment response in PD. Our previous research indicated that PD patients with increased dopamine transporter (DAT) and tyrosine hydroxylase (TH) in peripheral blood mononuclear cells (PBMCs) might show disease progression and respond to levodopa treatment...
May 18, 2024: Journal of Parkinson's Disease